Favipiravir-induced fever in coronavirus disease 2019: A report of two cases

Favipiravir, an antiviral agent, is undergoing clinical trials for treating novel coronavirus disease 2019 (COVID-19) We report two cases of COVID-19 with favipiravir-induced fever In both cases, pyrexia was observed following administration of favipiravir despite symptoms of COVID-19 improving No other cause for the fever was evident after careful physical examination and laboratory investigation Once favipiravir was discontinued, the fever subsided in both patients To our knowledge, this is the first report of favipiravir-induced fever